drugset / Trial / NCT00699010

Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse

NCT00699010

Phase 2 Completed 30 enrolled Acura Pharmaceuticals Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to assess the abuse liability of 4 times (8 tablets) the usual recommended dose of Acurox (oxycodone HCl 40 mg plus niacin 240 mg) versus oxycodone HCL 40 mg alone in subjects with a history of opioid abuse.

Timeline

Start
2008-03
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Niacin Small molecule 240 mg
Comparator Oxycodone Other / unclassified 40 mg

Indications